Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
3
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
acute hepatic porphyrias
akin akinc
alnylam pharmaceuticals
aminolevulinic acid
andrew berens
avapritinib
biopharma
biotech
blueprint medicines
cancer
deals
deciphera pharmaceuticals
drugs
duchenne
europe blog main
europe top stories
fda
gastrointestinal stromal tumor
gist
givosiran
gleevec
imatinib
licensing
m&a
muscular dystrophy
national top stories
onpattro
patisiran
paul matteis
regorafenib
ripretinib
rna interference
roche
sarepta therapeutics
What
approval
3
×
fda
medicine
3
×
drug
rna
second
seek
ago
alnylam
announced
betting
billion
biopharma
blueprint
cancer
chasing
deadly
deal
deciphera
duchenne
filing
forms
gene
gi
historic
indicated
interference
morning
nod
pharamceuticals
pharmaceuticals
plans
puts
quick
recently
rnai
roche
sarepta
speedy
swiss
Language
unset
Current search:
approval
×
boston
×
medicine
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug